Belatacept-based immunosuppression does not confer increased risk of BK polyomavirus-DNAemia relative to tacrolimus-based immunosuppression.

Emily M Eichenberger Wairimu MaguaJoseph B RickertGeeta KaradkheleMohammad Kazem FallahzadehPayaswini VasanthChristian Larsen

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2024)

Compared with tacrolimus-based immunosuppression, belatacept based immunosuppression was not associated with increased risk of BKPyV-DNAemia or nephropathy.

Keyphrases